June 01, 2010

Dr. Shannon Sheehan Travels to Washington

Dr. Shannon Sheehan travels to Washington.

Suppporting national patent legislation as well as state's biofuels and biomedical insudtries

New Mexico Biotechnology & Biomedical Association President Dr. Shannon Sheehan Promotes State's Bioscience Industry in Washington D.C.

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Jun 7, 2010 - In a move to advance the interests and accelerate the growth of New Mexico's emerging biotechnology and biomedical corridor, Dr. Shannon Sheehan, president of the New Mexico Biotechnology and Biomedical Association (NMBio) recently met with key state representatives in Washington D.C.

udall.bmpThe objective of the meetings was to ensure that the voice of NMBio is heard by New Mexico's federal legislative delegation and carried forth to a national level. Dr. Sheehan met with Senator Tom Udall and Congressman Harry Teague, as well as the staffs of Senator Bingaman, Congressman Martin Hienrich and Congressman Ben Lujan.

Dr. Sheehan's meetings are part of a national biotechnology industry effort to contribute meaningful dialog and informed decision making at the national level regarding patent legislation, health care reform, biologics, SBIR funding, as well as NIH funding of Cures Acceleration Network programs.

"New Mexico has all the key elements of an emerging biotech-biomed corridor that is positioned to become a hotbed for the bioscience industry in the coming years. Representing a growing industry, NMBio aims to be a key participant in national legislation and state initiatives that promote the advancement of bioscience and our member companies which range from the largest names in healthcare to the most promising high-tech start-ups," stated NMBio president Dr. Sheehan.

New Mexico's legislators in Washington expressed a strong interest in supporting the biomedical and biofuels industries. NMBio has a continuing dialog with law makers.

NMBio member companies include global bioscience leaders such as Johnson & Johnson, Genzyme, Pfizer, and Monsanto, as well as growing biomed companies including BioModa, IntelliCyt, and NanoMR. NMBio, in partnership with Los Alamos National Labs, Southwest Biofuels and NMBio member company Incitor, LLC is at the global forefront of biofuels.

 

Upcoming Events

  • Oct. 12, 2010 11:30 am, BioMedical Tuesday in Los Alamos, Quasi-Monte Carlo integration within a fixed reference frame provides an efficient method of transforming the volume of a specific molecular conformation into a binary encoding of the shape of that conformation. We explore the use of this method in terms of volume estimation, shape alignment, shape fingerprint generation, and shape/pharmacophore feature analysis, all in the general context of drug discovery.